OHSU

Casey Eye Institute at OHSU, Portland, Oregon

Where Healing, Teaching and Discovery Come Together


Ongoing Clinical Trials for AMD at Casey Eye Institute

 Susan Nolte

The GEM Study (Gene transfer of endostatin / angiostatin for Macular degeneration)

Purpose: To assess the safety and dosing levels of a gene-based treatment, RetinoStat®, for wet AMD. In this study, two corrective genes are delivered directly to the retina, with the aim of blocking the growth of abnormal blood vessels in a sustained fashion. Eligible patients must have established "wet" AMD with visual acuity equal or worse than 20/200 in the worse seeing eye.  There must be some ongoing leakage associated with the "wet" AMD and scarring at the center of the macula ("evolving disciform scar").

Contact: Ann Lundquist, 503 494-6364

 

 

Genetics of Age-Related Macular Degeneration Study

Purpose: To find genetic mechanisms associated with age-related macular degeneration. Large families with at least four living affected members are being recruited and followed. Volunteers receive eye photography and DNA analysis at no cost. No travel is required.

Contact: Jennifer Maykoski, 503 494-3064

 

 

Age-Related Eye Disease Study (AREDS2)

Purpose: To evaluate the effects of lutein and zeaxanthin and omega-3 fatty acids on people at risk of progressing to advanced AMD and/or suffering moderate vision loss. The study is being carried out at the Devers Eye Institute in Portland, which is one of the clinical centers sponsored by the National Eye Institute (NEI). Enrollment is completed and results are expected May 2013.  To learn more about the study and its results, visit www.areds2.org

Contact: Devers Eye Institute, 503 413-8356.

 

 

SEATTLE Study (Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride)

Purpose:  To learn if emixustat hydrochloride (ACU-4429), a cell cycle modifier, reduces the rate of progression of advanced dry AMD (geographic atrophy) compared to placebo in people with dry AMD.  The study medication is taken by mouth once daily.  Eligible patients must be older than age 55 with a clinical diagnosis of geographic atrophy associated with AMD.  Participants will also need to meet other criteria.

Contact:  Shelley Hanel, 503-494-1986

Stargardt Clinical Trials

Looking for information about clinical trials for Stargardt disease?

Please contact the study coordinator by e-mail or phone 503 494-3795.

Clinical Studies